Genoskin

Executive Summary

Genoskin is a French biotechnology company specializing in ex vivo human skin models for pharmaceutical, cosmetic, and chemical testing. Its proprietary technology keeps donated human skin alive and functional for at least seven days, offering a human-relevant alternative to animal testing. Founded in 2014 and headquartered in Toulouse, the company serves the growing demand for non-animal testing methods driven by ethical concerns and regulatory shifts, such as the EU's ban on animal testing for cosmetics and the FDA's push for alternative methodologies. Genoskin's models are used in drug delivery and dermatology research, with both ready-to-use products and custom non-clinical testing services. As a pre-clinical stage company, it has not yet disclosed funding or valuation but operates in a niche market with significant potential as regulatory frameworks evolve. The company faces competition from other in vitro testing providers but differentiates through its native human skin architecture and extended viability.

Upcoming Catalysts (preview)

• Q2 2026Potential Series A funding round to scale production and expand commercial reach60% success
• Q4 2026Strategic partnership with a major pharmaceutical or cosmetic company for preclinical testing services50% success
• TBDRegulatory endorsement or new guidelines favoring ex vivo human skin models over animal testing40% success